FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
What happened
FDA inspected Horizon Tool's Greensboro, NC drug manufacturing facility from January 14 to 16, 2025. FDA found the company lacked required microbiological testing for each batch of AllShield E2 Sanitizing Hand Soap, had no stability testing program for it, and did not adequately test incoming components, including benzalkonium chloride.
What FDA found
The company did not test each batch of AllShield E2 Sanitizing Hand Soap for objectionable microorganisms before release.
21 CFR 211.165(b)The company did not establish or follow a written stability testing program for AllShield E2 Sanitizing Hand Soap.
21 CFR 211.166(a)The company did not adequately test incoming components, including active ingredients and benzalkonium chloride solution, for identity and other required specifications.
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
FDA asks Horizon Tool to respond in writing within 15 working days with corrective actions, supporting documentation, independent assessments, and retrospective risk assessments for distributed batches. If the company cannot complete the actions in that time, it must give reasons and a completion schedule.
Who should pay attention
- brands that sell OTC antibacterial soaps
- contract manufacturers of OTC topical drug products
- suppliers and buyers of benzalkonium chloride or other drug ingredients
This is a summary. Read the original letter on fda.gov.